BeOne Medicines AG (ONC) Stock Score, Valuation & Financial Research
BeOne Medicines AG is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 64/100.
Quick answer for ONC
BeOne Medicines AG currently has a Wall Street Score of 64/100. The stored market price is $346.51. Its financial score is 39/100. Its valuation score is 97/100. These figures are a research snapshot, not a buy or sell recommendation.
What BeOne Medicines AG does
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted C
ONC financial snapshot
- Wall Street Score:
- 64/100
- Current price:
- $346.51
- Market capitalization:
- $37.03B
- Revenue:
- $5.74B
- Net income:
- $513.0M
- Free cash flow:
- $941.7M
- Cash:
- $4.79B
- Total debt:
- $1.15B
- EPS:
- 33.80
- P/E ratio:
- 10.3x
- Financial score:
- 39/100
- Valuation score:
- 97/100
- Revenue score:
- 34/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $941.7M, showing positive cash generation.
- The balance sheet shows $4.79B of cash versus $1.15B of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research ONC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.